{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:37:56Z","timestamp":1792708676996,"version":"4.5.0"},"reference-count":225,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02310-4","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T17:28:31Z","timestamp":1774718911000},"page":"813-840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current and Emerging Biologic Therapies for Severe Asthma"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6302-5060","authenticated-orcid":false,"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9877-7851","authenticated-orcid":false,"given":"Josuel","family":"Ora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-069X","authenticated-orcid":false,"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5040","authenticated-orcid":false,"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"2310_CR1","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention 2025 report. Available from: https:\/\/ginasthma.org\/2025-gina-strategy-report\/. [Accessed 29 Jan 2026]."},{"issue":"4","key":"2310_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","volume":"135","author":"PW Hekking","year":"2015","unstructured":"Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896\u2013902. https:\/\/doi.org\/10.1016\/j.jaci.2014.08.042.","journal-title":"J Allergy Clin Immunol"},{"issue":"10379","key":"2310_CR3","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","volume":"401","author":"C Porsbjerg","year":"2023","unstructured":"Porsbjerg C, Mel\u00e9n E, Lehtim\u00e4ki L, Shaw D. Asthma. Lancet. 2023;401(10379):858\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(22)02125-0.","journal-title":"Lancet"},{"issue":"11","key":"2310_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/S2213-2600(25)00299-1","volume":"13","author":"C Porsbjerg","year":"2025","unstructured":"Porsbjerg C, Rupani H, Brannan JD, et al. Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage. Lancet Respir Med. 2025;13(11):1026\u201340. https:\/\/doi.org\/10.1016\/S2213-2600(25)00299-1.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2310_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/02770903.2023.2248512","volume":"61","author":"L R\u00f6nnebjerg","year":"2024","unstructured":"R\u00f6nnebjerg L, Axelsson M, Kankaanranta H, Ekerljung L. Health-related quality of life, anxiety, depression, beliefs of medication, and self-efficacy in individuals with severe asthma: a population-based study. J Asthma. 2024;61(2):148\u201359. https:\/\/doi.org\/10.1080\/02770903.2023.2248512.","journal-title":"J Asthma"},{"issue":"4","key":"2310_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1378\/chest.13-1619","volume":"145","author":"M Sadatsafavi","year":"2014","unstructured":"Sadatsafavi M, Rousseau R, Chen W, Zhang W, Lynd L, FitzGerald JM. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study. Chest. 2014;145(4):787\u201393. https:\/\/doi.org\/10.1378\/chest.13-1619.","journal-title":"Chest"},{"issue":"3","key":"2310_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100518","volume":"4","author":"I Kull","year":"2025","unstructured":"Kull I, \u00d6dling M, Mogensen I, et al. Asthma increases short-time sickness absence and presenteeism in young adults. J Allergy Clin Immunol Glob. 2025;4(3):100518. https:\/\/doi.org\/10.1016\/j.jacig.2025.100518.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"10098","key":"2310_CR8","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S0140-6736(17)31448-4","volume":"390","author":"S Ebmeier","year":"2017","unstructured":"Ebmeier S, Thayabaran D, Braithwaite I, B\u00e9namara C, Weatherall M, Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). Lancet. 2017;390(10098):935\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(17)31448-4.","journal-title":"Lancet"},{"issue":"6","key":"2310_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/03007995.2025.2513963","volume":"41","author":"A Bourdin","year":"2025","unstructured":"Bourdin A, Vlachaki I, Madoni A, et al. A systematic review of the humanistic, economic, sociodemographic, and environmental burden of severe\/difficult-to-treat asthma. Curr Med Res Opin. 2025;41(6):1075\u201395. https:\/\/doi.org\/10.1080\/03007995.2025.2513963.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2310_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00703-2018","volume":"52","author":"T Volmer","year":"2018","unstructured":"Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. https:\/\/doi.org\/10.1183\/13993003.00703-2018.","journal-title":"Eur Respir J"},{"issue":"2","key":"2310_CR11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00700-2023","volume":"62","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Page CP, Matera MG, Rogliani P, Hanania NA. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023;62(2):2300700. https:\/\/doi.org\/10.1183\/13993003.00700-2023.","journal-title":"Eur Respir J"},{"issue":"1","key":"2310_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/a-2746-4469","volume":"47","author":"MF Pilia","year":"2026","unstructured":"Pilia MF, Espejo-Castellanos D, Romero-Mesones C, Mu\u00f1oz-Gall X, Ojanguren-Arranz I. Glucocorticoid treatment in severe asthma. Semin Respir Crit Care Med. 2026;47(1):122\u20139. https:\/\/doi.org\/10.1055\/a-2746-4469.","journal-title":"Semin Respir Crit Care Med"},{"issue":"10","key":"2310_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11882-019-0881-327","volume":"19","author":"X Li","year":"2019","unstructured":"Li X. Hot topic: precision medicine for asthma: has the time come? Curr Allergy Asthma Rep. 2019;19(10):45. https:\/\/doi.org\/10.1007\/s11882-019-0881-327.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"2310_CR14","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1172\/JCI124611","volume":"129","author":"I Agache","year":"2019","unstructured":"Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;129(4):1493\u2013503. https:\/\/doi.org\/10.1172\/JCI124611.","journal-title":"J Clin Invest"},{"issue":"1","key":"2310_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy JV. Type 2 inflammation in asthma: present in most, absent in many. Nat Rev Immunol. 2015;15(1):57\u201365. https:\/\/doi.org\/10.1038\/nri3786.","journal-title":"Nat Rev Immunol"},{"issue":"168","key":"2310_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0201-2022","volume":"32","author":"FLM Ricciardolo","year":"2023","unstructured":"Ricciardolo FLM, Guida G, Bertolini F, et al. Phenotype overlap in the natural history of asthma. Eur Respir Rev. 2023;32(168):220201. https:\/\/doi.org\/10.1183\/16000617.0201-2022.","journal-title":"Eur Respir Rev"},{"issue":"2","key":"2310_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03393-2020","volume":"58","author":"WW Busse","year":"2021","unstructured":"Busse WW, Kraft M, Rabe KF, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021;58(2):2003393. https:\/\/doi.org\/10.1183\/13993003.03393-2020.","journal-title":"Eur Respir J"},{"issue":"6","key":"2310_CR18","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.jaci.2013.01.035","volume":"131","author":"ML Fajt","year":"2013","unstructured":"Fajt ML, Gelhaus SL, Freeman B, et al. Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol. 2013;131(6):1504\u201312. https:\/\/doi.org\/10.1016\/j.jaci.2013.01.035.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2310_CR19","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1172\/JCI58978","volume":"122","author":"M Masuoka","year":"2012","unstructured":"Masuoka M, Shiraishi H, Ohta S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122(7):2590\u2013600. https:\/\/doi.org\/10.1172\/JCI58978.","journal-title":"J Clin Invest"},{"issue":"1","key":"2310_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/17476348.2021.1997597","volume":"16","author":"S van den Berg","year":"2022","unstructured":"van den Berg S, Hashimoto S, Golebski K, et al. Severe acute asthma at the pediatric intensive care unit: can we link the clinical phenotypes to immunological endotypes? Expert Rev Respir Med. 2022;16(1):25\u201334. https:\/\/doi.org\/10.1080\/17476348.2021.1997597.","journal-title":"Expert Rev Respir Med"},{"issue":"6","key":"2310_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-015-0529-x","volume":"15","author":"I Agache","year":"2015","unstructured":"Agache I, Sugita K, Morita H, et al. The complex type 2 endotype in allergy and asthma: from laboratory to bedside. Curr Allergy Asthma Rep. 2015;15(6):29. https:\/\/doi.org\/10.1007\/s11882-015-0529-x.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"2310_CR22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.04320","volume":"147","author":"WW Stevens","year":"2021","unstructured":"Stevens WW, Jerschow E, Baptist AP, et al. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a work group report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2021;147(3):827\u201344. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.04320.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2310_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannen LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133\u201341. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.063.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2310_CR24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00826-2023","volume":"64","author":"T Liu","year":"2024","unstructured":"Liu T, Woodruff PG, Zhou X. Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies. Eur Respir J. 2024;64(2):2300826. https:\/\/doi.org\/10.1183\/13993003.00826-2023.","journal-title":"Eur Respir J"},{"issue":"2","key":"2310_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.iac.2015.12.00122","volume":"36","author":"NG Papadopoulos","year":"2016","unstructured":"Papadopoulos NG, Guibas GV. Rhinitis subtypes, endotypes, and definitions. Immunol Allergy Clin North Am. 2016;36(2):215\u201333. https:\/\/doi.org\/10.1016\/j.iac.2015.12.00122.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"2310_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nm.267823","volume":"18","author":"SE Wenzel","year":"2012","unstructured":"Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716\u201325. https:\/\/doi.org\/10.1038\/nm.267823.","journal-title":"Nat Med"},{"issue":"2","key":"2310_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jaip.2019.11.00624","volume":"8","author":"AM Fitzpatrick","year":"2020","unstructured":"Fitzpatrick AM, Chipps BE, Holguin F, et al. T2-\u201clow\u201d asthma: overview and management strategies. J Allergy Clin Immunol Pract. 2020;8(2):452\u201363. https:\/\/doi.org\/10.1016\/j.jaip.2019.11.00624.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2310_CR28","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaip.2023.01.008","volume":"11","author":"S Couillard","year":"2023","unstructured":"Couillard S, Petousi N, Smigiel KS, et al. Toward a predict and prevent approach in obstructive airway diseases. J Allergy Clin Immunol Pract. 2023;11(3):704\u201312. https:\/\/doi.org\/10.1016\/j.jaip.2023.01.008.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2310_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.10130126","volume":"46","author":"I Agache","year":"2019","unstructured":"Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019;46:101301. https:\/\/doi.org\/10.1016\/j.smim.2019.10130126.","journal-title":"Semin Immunol"},{"issue":"1","key":"2310_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s41030-019-00109-1","volume":"6","author":"P Rogliani","year":"2020","unstructured":"Rogliani P, Calzetta L, Matera MG, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6(1):47\u201366. https:\/\/doi.org\/10.1007\/s41030-019-00109-1.","journal-title":"Pulm Ther"},{"issue":"8","key":"2310_CR31","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/1744666X.2025.2525443","volume":"21","author":"M Cazzola","year":"2025","unstructured":"Cazzola M, Hanania NA, Matera MG, Rogliani P. Biologics for severe asthma: deciphering what is best for the patient. Expert Rev Clin Immunol. 2025;21(8):1035\u201354. https:\/\/doi.org\/10.1080\/1744666X.2025.2525443.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2310_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010182","volume":"25","author":"CY Chen","year":"2023","unstructured":"Chen CY, Wu KH, Guo BC, et al. Personalized medicine in severe asthma: from biomarkers to biologics. Int J Mol Sci. 2023;25(1):182. https:\/\/doi.org\/10.3390\/ijms25010182.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2310_CR33","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1172\/JCI124606","volume":"129","author":"F Roan","year":"2019","unstructured":"Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. J Clin Invest. 2019;129(4):1441\u201351. https:\/\/doi.org\/10.1172\/JCI124606.","journal-title":"J Clin Invest"},{"issue":"9998","key":"2310_CR34","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","volume":"386","author":"KF Chung","year":"2015","unstructured":"Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015;386(9998):1086\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(15)00157-9.","journal-title":"Lancet"},{"issue":"2","key":"2310_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157\u201371. https:\/\/doi.org\/10.1056\/NEJMra2032506.","journal-title":"N Engl J Med"},{"key":"2310_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coi.2018.06.006","volume":"54","author":"M Kubo","year":"2018","unstructured":"Kubo M. Mast cells and basophils in allergic inflammation. Curr Opin Immunol. 2018;54:74\u20139. https:\/\/doi.org\/10.1016\/j.coi.2018.06.006.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"2310_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041226","volume":"11","author":"F Peri","year":"2023","unstructured":"Peri F, Amaddeo A, Badina L, Maschio M, Barbi E, Ghirardo S. T2-low asthma: a discussed but still orphan disease. Biomedicines. 2023;11(4):1226. https:\/\/doi.org\/10.3390\/biomedicines11041226.","journal-title":"Biomedicines"},{"issue":"3","key":"2310_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/ACI.0000000000000899","volume":"23","author":"KF Chung","year":"2023","unstructured":"Chung KF. Type-2-low severe asthma endotypes for new treatments: the new asthma frontier. Curr Opin Allergy Clin Immunol. 2023;23(3):199\u2013204. https:\/\/doi.org\/10.1097\/ACI.0000000000000899.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"2310_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-11007-y","volume":"53","author":"S Naz","year":"2025","unstructured":"Naz S, Wajid A, Malik MN, Tipu MK. Insights on inflammatory pathways and their cross-talk: a comprehensive review on asthma. Mol Biol Rep. 2025;53(1):36. https:\/\/doi.org\/10.1007\/s11033-025-11007-y.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"2310_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/JLB.3RU0121-023R","volume":"111","author":"EE Jean","year":"2022","unstructured":"Jean EE, Good O, Rico JMI, Rossi HL, Herbert DR. Neuroimmune regulatory networks of the airway mucosa in allergic inflammatory disease. J Leukoc Biol. 2022;111(1):209\u201321. https:\/\/doi.org\/10.1002\/JLB.3RU0121-023R.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"2310_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2021.12.769","volume":"149","author":"Y Xie","year":"2022","unstructured":"Xie Y, Abel PW, Casale TB, Tu Y. TH17 cells and corticosteroid insensitivity in severe asthma. J Allergy Clin Immunol. 2022;149(2):467\u201379. https:\/\/doi.org\/10.1016\/j.jaci.2021.12.769.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2310_CR42","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00528-2020","volume":"57","author":"TSC Hinks","year":"2021","unstructured":"Hinks TSC, Levine SJ, Brusselle GG. Treatment options in type-2 low asthma. Eur Respir J. 2021;57(1):2000528. https:\/\/doi.org\/10.1183\/13993003.00528-2020.","journal-title":"Eur Respir J"},{"key":"2310_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975914","volume":"13","author":"M Duchesne","year":"2022","unstructured":"Duchesne M, Okoye I, Lacy P. Epithelial cell alarmin cytokines: frontline mediators of the asthma inflammatory response. Front Immunol. 2022;13:975914. https:\/\/doi.org\/10.3389\/fimmu.2022.975914.","journal-title":"Front Immunol"},{"issue":"2","key":"2310_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/all.15609","volume":"78","author":"GM Gauvreau","year":"2023","unstructured":"Gauvreau GM, Bergeron C, Boulet LP, et al. Sounding the alarmins: the role of alarmin cytokines in asthma. Allergy. 2023;78(2):402\u201317. https:\/\/doi.org\/10.1111\/all.15609.","journal-title":"Allergy"},{"issue":"4","key":"2310_CR45","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2025.01.017","volume":"155","author":"A Akenroye","year":"2025","unstructured":"Akenroye A, Boyce JA, Kita H. Targeting alarmins in asthma: from bench to clinic. J Allergy Clin Immunol. 2025;155(4):1133\u201348. https:\/\/doi.org\/10.1016\/j.jaci.2025.01.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"167","key":"2310_CR46","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0144-2022","volume":"32","author":"AA Calderon","year":"2023","unstructured":"Calderon AA, Dimond C, Choy DF, et al. Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD. Eur Respir Rev. 2023;32(167):220144. https:\/\/doi.org\/10.1183\/16000617.0144-2022.","journal-title":"Eur Respir Rev"},{"issue":"10516","key":"2310_CR47","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","volume":"406","author":"E Israel","year":"2025","unstructured":"Israel E, Wechsler ME, Jackson DJ, Moore WC. Anti-cytokine biologics for asthma in adults. Lancet. 2025;406(10516):2282\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(25)01625-3.","journal-title":"Lancet"},{"issue":"13","key":"2310_CR48","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.3390\/jcm14134749","volume":"14","author":"M D'Amato","year":"2025","unstructured":"D\u2019Amato M, Pastore D, Lupia C, et al. Biologic therapy in severe asthma: a phenotype-driven and targeted approach. J Clin Med. 2025;14(13):4749. https:\/\/doi.org\/10.3390\/jcm14134749.","journal-title":"J Clin Med"},{"issue":"24","key":"2310_CR49","doi-asserted-by":"publisher","first-page":"9975","DOI":"10.1074\/jbc.M117.776476","volume":"292","author":"AM Davies","year":"2017","unstructured":"Davies AM, Allan EG, Keeble AH, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem. 2017;292(24):9975\u201387. https:\/\/doi.org\/10.1074\/jbc.M117.776476.","journal-title":"J Biol Chem"},{"issue":"7","key":"2310_CR50","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","volume":"9","author":"J Bousquet","year":"2021","unstructured":"Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 2021;9(7):2702\u201314. https:\/\/doi.org\/10.1016\/j.jaip.2021.01.011.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2310_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.37349\/eaa.2024.00047","volume":"2","author":"KC Bergmann","year":"2024","unstructured":"Bergmann KC, Hartung T, Kugler S, Stevanovic K, Zuberbier T. Long-term evaluation of omalizumab therapy in patients with severe allergic asthma. Explor Asthma Allergy. 2024;2:319\u201328. https:\/\/doi.org\/10.37349\/eaa.2024.00047.","journal-title":"Explor Asthma Allergy"},{"key":"2310_CR52","unstructured":"Global Initiative for Asthma. Difficult-to-treat & severe asthma guide. Available from: https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/11\/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf. [Accessed 23 Mar 2026]."},{"issue":"10","key":"2310_CR53","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.clinthera.2019.07.021","volume":"41","author":"A Kavati","year":"2019","unstructured":"Kavati A, Zhdanava M, Ortiz B, et al. Retrospective study on the association of biomarkers with real-world outcomes of omalizumab-treated patients with allergic asthma. Clin Ther. 2019;41(10):1956\u201371. https:\/\/doi.org\/10.1016\/j.clinthera.2019.07.021.","journal-title":"Clin Ther"},{"issue":"6","key":"2310_CR54","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","volume":"120","author":"L Cox","year":"2007","unstructured":"Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373\u20137. https:\/\/doi.org\/10.1016\/j.jaci.2007.09.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2310_CR55","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2500\/aap.2015.36.3849","volume":"36","author":"JL Zazzali","year":"2015","unstructured":"Zazzali JL, Raimundo KP, Trzaskoma B, Ros\u00e9n KE, Schatz M. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. Allergy Asthma Proc. 2015;36(4):283\u201392. https:\/\/doi.org\/10.2500\/aap.2015.36.3849.","journal-title":"Allergy Asthma Proc"},{"issue":"12","key":"2310_CR56","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s40265-023-01905-5","volume":"83","author":"C Domingo","year":"2023","unstructured":"Domingo C, Mirapeix RM, Gonz\u00e1lez-Barcala FJ, Forn\u00e9 C, Garc\u00eda F. Omalizumab in severe asthma: effect on oral corticosteroid exposure and remodeling. A randomized open-label parallel study. Drugs. 2023;83(12):1111\u201323. https:\/\/doi.org\/10.1007\/s40265-023-01905-5.","journal-title":"Drugs"},{"issue":"4","key":"2310_CR57","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/14712598.2021.1882990","volume":"21","author":"F Menzella","year":"2021","unstructured":"Menzella F, Ferrari E, Ferrucci SM, et al. Self-administration of omalizumab: why not? A literature review and expert opinion. Expert Opin Biol Ther. 2021;21(4):499\u2013507. https:\/\/doi.org\/10.1080\/14712598.2021.1882990.","journal-title":"Expert Opin Biol Ther"},{"issue":"9842","key":"2310_CR58","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(12)60988-X.","journal-title":"Lancet"},{"issue":"13","key":"2310_CR59","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa1403290.","journal-title":"N Engl J Med"},{"issue":"7","key":"2310_CR60","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549\u201356. https:\/\/doi.org\/10.1016\/S2213-2600(16)30031-5.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"2310_CR61","doi-asserted-by":"publisher","first-page":"9425","DOI":"10.21037\/jtd-2025-1596","volume":"17","author":"Y Li","year":"2025","unstructured":"Li Y, Li J, Yang H, Wu L. Efficacy and safety of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis. J Thorac Dis. 2025;17(11):9425\u201338. https:\/\/doi.org\/10.21037\/jtd-2025-1596.","journal-title":"J Thorac Dis"},{"issue":"6","key":"2310_CR62","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/j.clinthera.2021.03.023","volume":"43","author":"H Li","year":"2021","unstructured":"Li H, Zhang Q, Wang J, et al. Real-world effectiveness of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis. Clin Ther. 2021;43(6):e192-208. https:\/\/doi.org\/10.1016\/j.clinthera.2021.03.023.","journal-title":"Clin Ther"},{"issue":"10351","key":"2310_CR63","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","volume":"400","author":"DJ Jackson","year":"2022","unstructured":"Jackson DJ, Bacharier LB, Gergen PJ, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet. 2022;400(10351):502\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(22)01198-9.","journal-title":"Lancet"},{"issue":"2","key":"2310_CR64","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","volume":"158","author":"JE Kavanagh","year":"2020","unstructured":"Kavanagh JE, d\u2019Ancona G, Elstad M, et al. Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491\u2013500. https:\/\/doi.org\/10.1016\/j.chest.2020.03.042.","journal-title":"Chest"},{"issue":"9","key":"2310_CR65","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1111\/all.16618","volume":"80","author":"F Schleich","year":"2025","unstructured":"Schleich F, Loukides S, Chaudhuri R, et al. Mepolizumab effectiveness in severe asthma with\/without chronic rhinosinusitis with nasal polyps: real-world pooled analysis. Allergy. 2025;80(9):2557\u201371. https:\/\/doi.org\/10.1111\/all.16618.","journal-title":"Allergy"},{"key":"2310_CR66","doi-asserted-by":"publisher","unstructured":"Taill\u00e9 C, Hamidi F, Heddebaut N, et al. Impact of mepolizumab on airway remodeling and inflammation in severe eosinophilic asthma. Chest. 2025. Online ahead of print. https:\/\/doi.org\/10.1016\/j.chest.2025.10.047.","DOI":"10.1016\/j.chest.2025.10.047"},{"issue":"12","key":"2310_CR67","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1016\/j.jaip.2025.07.049","volume":"13","author":"G Chupp","year":"2025","unstructured":"Chupp G, Heaney LG, Pelaia G, et al. Impact of demographics on mepolizumab effectiveness in severe asthma: one-year REALITI-A subanalysis. J Allergy Clin Immunol Pract. 2025;13(12):3286\u201395. https:\/\/doi.org\/10.1016\/j.jaip.2025.07.049.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"2310_CR68","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1080\/02770903.2025.2558755","volume":"62","author":"GW Canonica","year":"2025","unstructured":"Canonica GW, Bourdin A, Penz E, Zhang L, Howarth P, Alfonso-Cristancho R. Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma during the REALITI-A 2-year study. J Asthma. 2025;62(12):2114\u201324. https:\/\/doi.org\/10.1080\/02770903.2025.2558755.","journal-title":"J Asthma"},{"issue":"17","key":"2310_CR69","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","volume":"377","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1708208.","journal-title":"N Engl J Med"},{"key":"2310_CR70","doi-asserted-by":"publisher","unstructured":"Matera MG, De Novellis V, Rogliani P, Cazzola M. A review of the safety of antibody therapy in severe eosinophilic asthma. Expert Rev Respir Med. 2025. Online ahead of print. https:\/\/doi.org\/10.1080\/17476348.2025.2607151","DOI":"10.1080\/17476348.2025.2607151"},{"issue":"4","key":"2310_CR71","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","volume":"150","author":"L Bjermer","year":"2016","unstructured":"Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: aa randomized phase 3 study. Chest. 2016;150(4):789\u201398. https:\/\/doi.org\/10.1016\/j.chest.2016.03.032.","journal-title":"Chest"},{"issue":"4","key":"2310_CR72","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799\u2013810. https:\/\/doi.org\/10.1016\/j.chest.2016.03.018.","journal-title":"Chest"},{"issue":"3","key":"2310_CR73","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/02770903.2016.1212371","volume":"54","author":"J Li","year":"2017","unstructured":"Li J, Wang F, Lin C, et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: a systematic review and meta-analysis. J Asthma. 2017;54(3):300\u20137. https:\/\/doi.org\/10.1080\/02770903.2016.1212371.","journal-title":"J Asthma"},{"issue":"5","key":"2310_CR74","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.chest.2020.11.060","volume":"159","author":"ME Wechsler","year":"2021","unstructured":"Wechsler ME, Peters SP, Hill TD, et al. Clinical outcomes and health-care resource use associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice. Chest. 2021;159(5):1734\u201346. https:\/\/doi.org\/10.1016\/j.chest.2020.11.060.","journal-title":"Chest"},{"issue":"8","key":"2310_CR75","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.jaip.2022.04.014","volume":"10","author":"S Hashimoto","year":"2022","unstructured":"Hashimoto S, Kroes JA, Eger KA, et al. Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma: first initiators and switchers. J Allergy Clin Immunol Pract. 2022;10(8):2099-108.e6. https:\/\/doi.org\/10.1016\/j.jaip.2022.04.014.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2310_CR76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/JAA.S340562","volume":"15","author":"LA P\u00e9rez de Llano","year":"2022","unstructured":"P\u00e9rez de Llano LA, Cos\u00edo BG, Lobato Asti\u00e1rraga I, et al. Asthma control in patients with severe eosinophilic asthma treated with reslizumab: Spanish real-life data. J Asthma Allergy. 2022;15:79\u201388. https:\/\/doi.org\/10.2147\/JAA.S340562.","journal-title":"J Asthma Allergy"},{"issue":"2","key":"2310_CR77","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bcp.15002","volume":"88","author":"D Singh","year":"2022","unstructured":"Singh D, Fuhr R, Bird NP, et al. A phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022;88(2):702\u201312. https:\/\/doi.org\/10.1111\/bcp.15002.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2310_CR78","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/cpt.70183","volume":"119","author":"C Zecchin","year":"2026","unstructured":"Zecchin C, Schalkwijk S, Pouliquen IJ, et al. Straight to phase III: model-informed approach speeds depemokimab clinical development in interleukin-5-driven diseases. Clin Pharmacol Ther. 2026;119(4):1005\u201315. https:\/\/doi.org\/10.1002\/cpt.70183.","journal-title":"Clin Pharmacol Ther"},{"issue":"24","key":"2310_CR79","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024;391(24):2337\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2406673.","journal-title":"N Engl J Med"},{"key":"2310_CR80","unstructured":"GSK Regulatory News. Pooled SWIFT and AGILE extension results for depemokimab in severe asthma. London Stock Exchange Regulatory News Service. 2025. Available from: https:\/\/www.lse.co.uk\/rns\/GSK\/exdensur-depemokimab-uk-mhra-approval-nwijmfd8jkbnutt.html. [Accessed 29 Jan 2026]."},{"issue":"1","key":"2310_CR81","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","volume":"13","author":"S Ramakrishnan","year":"2025","unstructured":"Ramakrishnan S, Russell REK, Mahmood HR, et al. Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial. Lancet Respir Med. 2025;13(1):59\u201368. https:\/\/doi.org\/10.1016\/S2213-2600(24)00299-6.","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"2310_CR82","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(16)31324-1.","journal-title":"Lancet"},{"issue":"10056","key":"2310_CR83","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(16)31322-8.","journal-title":"Lancet"},{"issue":"25","key":"2310_CR84","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448\u201358. https:\/\/doi.org\/10.1056\/NEJMoa1703501.","journal-title":"N Engl J Med"},{"issue":"2","key":"2310_CR85","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","volume":"159","author":"JE Kavanagh","year":"2021","unstructured":"Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496\u2013506. https:\/\/doi.org\/10.1016\/j.chest.2020.08.2083.","journal-title":"Chest"},{"issue":"1","key":"2310_CR86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.chest.2025.04.011","volume":"168","author":"G Pelaia","year":"2025","unstructured":"Pelaia G, Jackson DJ, Nair P, et al. XALOC-1: clinical remission over 2 years with benralizumab in severe eosinophilic asthma. Chest. 2025;168(1):19\u201332. https:\/\/doi.org\/10.1016\/j.chest.2025.04.011.","journal-title":"Chest"},{"issue":"1","key":"2310_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02439-w","volume":"24","author":"A Vultaggio","year":"2023","unstructured":"Vultaggio A, Aliani M, Altieri E, et al. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study. Respir Res. 2023;24(1):135. https:\/\/doi.org\/10.1186\/s12931-023-02439-w.","journal-title":"Respir Res"},{"issue":"13","key":"2310_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134362","volume":"12","author":"G Scioscia","year":"2023","unstructured":"Scioscia G, Tondo P, Nolasco S, et al. Benralizumab in patients with severe eosinophilic asthma: a multicentre real-life experience. J Clin Med. 2023;12(13):4362. https:\/\/doi.org\/10.3390\/jcm12134362.","journal-title":"J Clin Med"},{"issue":"1","key":"2310_CR89","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000548349","volume":"105","author":"M Lommatzsch","year":"2026","unstructured":"Lommatzsch M, Watz H, Grund T, Plate T, Saathoff M, Korn S. Benralizumab-induced asthma remission: impact of different tools and thresholds to define good asthma control. Respiration. 2026;105(1):12\u201321. https:\/\/doi.org\/10.1159\/000548349.","journal-title":"Respiration"},{"issue":"22","key":"2310_CR90","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015868","volume":"98","author":"W Liu","year":"2019","unstructured":"Liu W, Ma X, Zhou W. Adverse events of benralizumab in moderate to severe eosinophilic asthma: a meta-analysis. Medicine (Baltimore). 2019;98(22):e15868. https:\/\/doi.org\/10.1097\/MD.0000000000015868.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2310_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44973-z","volume":"13","author":"S Park","year":"2023","unstructured":"Park S, Kim Y, Lee GH, Choi SA. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database. Sci Rep. 2023;13(1):17607. https:\/\/doi.org\/10.1038\/s41598-023-44973-z.","journal-title":"Sci Rep"},{"issue":"6","key":"2310_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060974","volume":"10","author":"C Pelaia","year":"2022","unstructured":"Pelaia C, Pelaia G, Crimi C, et al. Biological therapy of severe asthma with dupilumab, a dual receptor antagonist of interleukins 4 and 13. Vaccines. 2022;10(6):974. https:\/\/doi.org\/10.3390\/vaccines10060974.","journal-title":"Vaccines"},{"issue":"11","key":"2310_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.71391","volume":"60","author":"A Ghadah","year":"2025","unstructured":"Ghadah A, Aryam A, Shahad A, et al. Efficacy and safety of dupilumab in children with moderate-to-severe asthma: a systematic review of emerging phase 3 evidence. Pediatr Pulmonol. 2025;60(11):e71391. https:\/\/doi.org\/10.1002\/ppul.71391.","journal-title":"Pediatr Pulmonol"},{"issue":"26","key":"2310_CR94","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","journal-title":"N Engl J Med"},{"issue":"26","key":"2310_CR95","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa1804093.","journal-title":"N Engl J Med"},{"issue":"4","key":"2310_CR96","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1513\/AnnalsATS.202306-544RL","volume":"21","author":"A Papi","year":"2024","unstructured":"Papi A, Castro M, Busse WW, et al. Long-term dupilumab efficacy on severe exacerbations and lung function in patients with type 2 asthma. Ann Am Thorac Soc. 2024;21(4):675\u20139. https:\/\/doi.org\/10.1513\/AnnalsATS.202306-544RL.","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"2310_CR97","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","volume":"13","author":"M Castro","year":"2025","unstructured":"Castro M, Papi A, Porsbjerg C, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13(3):208\u201320. https:\/\/doi.org\/10.1016\/S2213-2600(24)00362-X.","journal-title":"Lancet Respir Med"},{"key":"2310_CR98","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202410-1894OC","author":"C Porsbjerg","year":"2025","unstructured":"Porsbjerg C, Dunican EM, Lugogo NL, et al. Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial. Am J Respir Crit Care Med. 2025. https:\/\/doi.org\/10.1164\/rccm.202410-1894OC. (Online ahead of print).","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2310_CR99","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaci.2025.06.037","volume":"156","author":"GR Washko","year":"2025","unstructured":"Washko GR, Lipworth BJ, Saralaya D, et al. Effect of dupilumab on small airways measured by airway oscillometry in VESTIGE. J Allergy Clin Immunol. 2025;156(5):1209\u201318. https:\/\/doi.org\/10.1016\/j.jaci.2025.06.037.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2310_CR100","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S2213-2600(25)00287-5","volume":"13","author":"E De Corso","year":"2025","unstructured":"De Corso E, Canonica GW, Heffler E, et al. Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. Lancet Respir Med. 2025;13(12):1067\u201377. https:\/\/doi.org\/10.1016\/S2213-2600(25)00287-5.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"2310_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100533","volume":"4","author":"C M\u00fcmmler","year":"2025","unstructured":"M\u00fcmmler C, Lenoir A, G\u00f6tschke J, et al. Long-term outcomes of dupilumab therapy in severe asthma: a retrospective, multicenter, real-world study. J Allergy Clin Immunol Glob. 2025;4(4):100533. https:\/\/doi.org\/10.1016\/j.jacig.2025.100533.","journal-title":"J Allergy Clin Immunol Glob."},{"issue":"6","key":"2310_CR102","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.jaci.2024.07.029","volume":"154","author":"E Bleecker","year":"2024","unstructured":"Bleecker E, Blaiss M, Jacob-Nara J, et al. Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: real-world US ADVANTAGE study. J Allergy Clin Immunol. 2024;154(6):1500\u201310. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2310_CR103","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jaip.2025.04.015","volume":"13","author":"CT Hung","year":"2025","unstructured":"Hung CT, Hung YC, Suk CW. Comparative effectiveness of dupilumab versus mepolizumab and benralizumab in asthma: a multinational retrospective cohort study. J Allergy Clin Immunol Pract. 2025;13(7):1707-16.e10. https:\/\/doi.org\/10.1016\/j.jaip.2025.04.015.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2310_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2026.108647","volume":"252","author":"M Maniscalco","year":"2026","unstructured":"Maniscalco M, Candia C, Ambrosino P, Matera MG, Cazzola M. Fractional exhaled nitric oxide in monitoring biological treatment for severe asthma in adults: clinical implications and future perspectives. Respir Med. 2026;252:108647. https:\/\/doi.org\/10.1016\/j.rmed.2026.108647.","journal-title":"Respir Med"},{"issue":"9","key":"2310_CR105","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/17460441.2023.2230885","volume":"18","author":"MG Matera","year":"2023","unstructured":"Matera MG, Ora J, Rogliani P, Cazzola M. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma. Expert Opin Drug Discov. 2023;18(9):951\u201363. https:\/\/doi.org\/10.1080\/17460441.2023.2230885.","journal-title":"Expert Opin Drug Discov"},{"issue":"10","key":"2310_CR106","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1704064.","journal-title":"N Engl J Med"},{"issue":"19","key":"2310_CR107","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2034975.","journal-title":"N Engl J Med"},{"issue":"1","key":"2310_CR108","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","volume":"208","author":"J Corren","year":"2023","unstructured":"Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13\u201324. https:\/\/doi.org\/10.1164\/rccm.202210-2005OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2310_CR109","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32156","volume":"14","author":"P Roy","year":"2022","unstructured":"Roy P, Rafa ZI, Haque SN, et al. The impact of tezepelumab in uncontrolled severe asthma: a systematic review of randomized controlled trials. Cureus. 2022;14(12):e32156. https:\/\/doi.org\/10.7759\/cureus.32156.","journal-title":"Cureus"},{"issue":"7","key":"2310_CR110","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;10(7):650\u201360. https:\/\/doi.org\/10.1016\/S2213-2600(21)00537-3.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2310_CR111","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-2600(25)00359-5","volume":"14","author":"DJ Jackson","year":"2026","unstructured":"Jackson DJ, Lugogo NL, Gurnell M, et al. Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial. Lancet Respir Med. 2026;14(2):129\u201340. https:\/\/doi.org\/10.1016\/S2213-2600(25)00359-5.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"2310_CR112","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","volume":"11","author":"A Menzies-Gow","year":"2023","unstructured":"Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023;11(5):425\u201338. https:\/\/doi.org\/10.1016\/S2213-2600(22)00492-1.","journal-title":"Lancet Respir Med"},{"key":"2310_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115185","volume":"162","author":"C Pelaia","year":"2025","unstructured":"Pelaia C, Greco M, Iaccino E, et al. Short-term therapeutic effectiveness of tezepelumab in patients with severe asthma: a real-world study. Int Immunopharmacol. 2025;162:115185. https:\/\/doi.org\/10.1016\/j.intimp.2025.115185.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"2310_CR114","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1111\/all.16590","volume":"80","author":"J Gates","year":"2025","unstructured":"Gates J, Haris F, Cefaloni F, et al. Clinical and biological remission with tezepelumab: the real-world response in severe uncontrolled asthma. Allergy. 2025;80(6):1669\u201376. https:\/\/doi.org\/10.1111\/all.16590.","journal-title":"Allergy"},{"key":"2310_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.106528","volume":"143","author":"R Poto","year":"2026","unstructured":"Poto R, Manganello G, di Salvatore A, et al. Effectiveness of tezepelumab in severe asthma: a multicenter real-world study. Eur J Intern Med. 2026;143:106528. https:\/\/doi.org\/10.1016\/j.ejim.2025.106528.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"2310_CR116","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaci.2016.10.034","volume":"140","author":"FLM Ricciardolo","year":"2017","unstructured":"Ricciardolo FLM, Sorbello V, Folino A, et al. Identification of IL-17F\/frequent exacerbator endotype in asthma. J Allergy Clin Immunol. 2017;140(2):395\u2013406. https:\/\/doi.org\/10.1016\/j.jaci.2016.10.034.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2310_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01620-3","volume":"8","author":"L Huangfu","year":"2023","unstructured":"Huangfu L, Li R, Huang Y, Wang S. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther. 2023;8(1):402. https:\/\/doi.org\/10.1038\/s41392-023-01620-3.","journal-title":"Signal Transduct Target Ther"},{"key":"2310_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.983852","volume":"13","author":"G Kardas","year":"2022","unstructured":"Kardas G, Panek M, Kuna P, Damia\u0144ski P, Kupczyk M. Monoclonal antibodies in the management of asthma: dead ends, current status and future perspectives. Front Immunol. 2022;13:983852. https:\/\/doi.org\/10.3389\/fimmu.2022.983852.","journal-title":"Front Immunol"},{"issue":"11","key":"2310_CR119","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","volume":"188","author":"WW Busse","year":"2013","unstructured":"Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294\u2013302. https:\/\/doi.org\/10.1164\/rccm.201212-2318OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"2310_CR120","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/JAA.S496630","volume":"18","author":"AW Lindsley","year":"2025","unstructured":"Lindsley AW, Lugogo N, Reeh KAG, Spahn J, Parnes JR. Asthma biologics across the T2 spectrum of inflammation in severe asthma: biomarkers and mechanism of action. J Asthma Allergy. 2025;18:33\u201357. https:\/\/doi.org\/10.2147\/JAA.S496630.","journal-title":"J Asthma Allergy"},{"issue":"18","key":"2310_CR121","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","volume":"385","author":"CE Brightling","year":"2021","unstructured":"Brightling CE, Nair P, Cousins DJ, Louis R, Singh D. Risankizumab in severe asthma: a phase 2a, placebo-controlled trial. N Engl J Med. 2021;385(18):1669\u201379. https:\/\/doi.org\/10.1056\/NEJMoa2030880.","journal-title":"N Engl J Med"},{"issue":"6","key":"2310_CR122","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1044","volume":"8","author":"JA Revez","year":"2019","unstructured":"Revez JA, Bain LM, Watson RM, et al. Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics. Clin Transl Immunol. 2019;8(6):e1044. https:\/\/doi.org\/10.1002\/cti2.1044.","journal-title":"Clin Transl Immunol"},{"issue":"2","key":"2310_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020321","volume":"14","author":"D Laorden","year":"2025","unstructured":"Laorden D, Dom\u00ednguez-Ortega J, Romero D, et al. Efficacy assessment of biological treatments in severe asthma. J Clin Med. 2025;14(2):321. https:\/\/doi.org\/10.3390\/jcm14020321.","journal-title":"J Clin Med"},{"issue":"9","key":"2310_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093153","volume":"14","author":"N Faria","year":"2025","unstructured":"Faria N, Costa MI, Fernandes AL, et al. Biologic therapies for severe asthma: current insights and future directions. J Clin Med. 2025;14(9):3153. https:\/\/doi.org\/10.3390\/jcm14093153.","journal-title":"J Clin Med"},{"issue":"4","key":"2310_CR125","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaci.2025.05.031","volume":"156","author":"PJ McDowell","year":"2025","unstructured":"McDowell PJ, Azim A, Busby J, et al. Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma. J Allergy Clin Immunol. 2025;156(4):911\u201322. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"10422","key":"2310_CR126","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","volume":"403","author":"M Maurer","year":"2024","unstructured":"Maurer M, Ensina LF, Gimenez-Arnau AM, et al. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. 2024;403(10422):147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(23)01684-7.","journal-title":"Lancet"},{"issue":"3","key":"2310_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1255","volume":"10","author":"J Trischler","year":"2021","unstructured":"Trischler J, Bottoli I, Janocha R, et al. Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Clin Transl Immunol. 2021;10(3):e1255. https:\/\/doi.org\/10.1002\/cti2.1255.","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"2310_CR128","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","volume":"11","author":"P Gasser","year":"2020","unstructured":"Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165. https:\/\/doi.org\/10.1038\/s41467-019-13815-w.","journal-title":"Nat Commun"},{"key":"2310_CR129","unstructured":"AdisInsight. Ligelizumab: Novartis. Available from: https:\/\/adisinsight.springer.com\/drugs\/800033626. [Accessed 11 Mar 2026]."},{"key":"2310_CR130","unstructured":"RAPT Therapeutics, RAPT Therapeutics and Shanghai Jeyou Pharmaceutical announce positive topline data from phase 2 trial of RPT904 (JYB1904) in chronic spontaneous urticaria. Available from: https:\/\/rapt.com\/news\/rapt-therapeutics-and-shanghai-jeyou-pharmaceutical-announce-positive-topline-data-from-phase-2-trial-of-rpt904-jyb1904-in-chronic-spontaneous-urticaria\/#:~:text=RAPT%20Therapeutics%20and%20Shanghai%20Jeyou,Chronic%20Spontaneous%20Urticaria%20%2D%20RAPT%20Therapeutics. [Accessed 29 Jan 2026]."},{"issue":"2","key":"2310_CR131","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1208\/s12248-008-9045-4","volume":"10","author":"WS Putnam","year":"2008","unstructured":"Putnam WS, Li J, Haggstrom J, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J. 2008;10(2):425\u201330. https:\/\/doi.org\/10.1208\/s12248-008-9045-4.","journal-title":"AAPS J"},{"issue":"6","key":"2310_CR132","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4161\/mabs.22216","volume":"4","author":"DL Mortensen","year":"2012","unstructured":"Mortensen DL, Prabhu S, Stefanich EG, et al. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs. 2012;4(6):724\u201331. https:\/\/doi.org\/10.4161\/mabs.22216.","journal-title":"MAbs"},{"issue":"6","key":"2310_CR133","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70074","volume":"15","author":"K Guan","year":"2025","unstructured":"Guan K, Liu S, Feng Y, et al. LP-003, a novel high-affinity anti-IgE antibody for inadequately controlled seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial. Clin Transl Allergy. 2025;15(6):e70074. https:\/\/doi.org\/10.1002\/clt2.70074.","journal-title":"Clin Transl Allergy."},{"issue":"15","key":"2310_CR134","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157765","volume":"132","author":"BS Kuo","year":"2022","unstructured":"Kuo BS, Li CH, Chen JB, et al. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms. J Clin Invest. 2022;132(15):e157765. https:\/\/doi.org\/10.1172\/JCI157765.","journal-title":"J Clin Invest"},{"issue":"6","key":"2310_CR135","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1172\/JCI40141","volume":"120","author":"HD Brightbill","year":"2010","unstructured":"Brightbill HD, Jeet S, Lin Z, et al. Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest. 2010;120(6):2218\u201329. https:\/\/doi.org\/10.1172\/JCI40141.","journal-title":"J Clin Invest"},{"key":"2310_CR136","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12931-016-0347-2","volume":"17","author":"JM Harris","year":"2016","unstructured":"Harris JM, Maciuca R, Bradley MS, et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res. 2016;17:29. https:\/\/doi.org\/10.1186\/s12931-016-0347-2.","journal-title":"Respir Res"},{"issue":"4","key":"2310_CR137","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jaci.2011.11.029","volume":"129","author":"SY Chu","year":"2012","unstructured":"Chu SY, Horton HM, Pong E, et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and Fc\u03b3RIIb with Fc-engineered antibody. J Allergy Clin Immunol. 2012;129(4):1102\u201315. https:\/\/doi.org\/10.1016\/j.jaci.2011.11.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2310_CR138","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.1038\/s41467-022-33176-1","volume":"13","author":"SB An","year":"2022","unstructured":"An SB, Yang BG, Jang G, et al. Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy. Nat Commun. 2022;13(1):5669. https:\/\/doi.org\/10.1038\/s41467-022-33176-1.","journal-title":"Nat Commun"},{"issue":"2","key":"2310_CR139","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4168\/aair.2025.17.2.181","volume":"17","author":"MS Ryu","year":"2025","unstructured":"Ryu MS, Yang EM, Ye YM, et al. Therapeutic efficacy of YH35324 on Fc\u03b5RI\u03b1-mediated mast cell\/basophil activation. Allergy Asthma Immunol Res. 2025;17(2):181\u201395. https:\/\/doi.org\/10.4168\/aair.2025.17.2.181.","journal-title":"Allergy Asthma Immunol Res"},{"key":"2310_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111706","volume":"130","author":"YM Ye","year":"2024","unstructured":"Ye YM, Park JW, Kim SH, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of YH35324, a novel long-acting high-affinity IgETrap-Fc protein in subjects with atopy: results from the first-in-human study. Int Immunopharmacol. 2024;130:111706. https:\/\/doi.org\/10.1016\/j.intimp.2024.111706.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2310_CR141","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/19420862.2015.1119352","volume":"8","author":"C Panousis","year":"2016","unstructured":"Panousis C, Dhagat U, Edwards KM, et al. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common \u03b2 chain of the IL-3, GM-CSF and IL-5 receptors. MAbs. 2016;8(3):436\u201353. https:\/\/doi.org\/10.1080\/19420862.2015.1119352.","journal-title":"MAbs"},{"issue":"3","key":"2310_CR142","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jaci.2023.10.021","volume":"153","author":"H Wang","year":"2024","unstructured":"Wang H, Yip KH, Keam SP, et al. Dual inhibition of airway inflammation and fibrosis by common \u03b2 cytokine receptor blockade. J Allergy Clin Immunol. 2024;153(3):672-83.e6. https:\/\/doi.org\/10.1016\/j.jaci.2023.10.021.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2310_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04589-z","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Tumes DJ, Hercus TR, et al. Blocking the human common beta subunit of the GM-CSF, IL-5 and IL-3 receptors markedly reduces hyperinflammation in ARDS models. Cell Death Dis. 2022;13(2):137. https:\/\/doi.org\/10.1038\/s41419-022-04589-z.","journal-title":"Cell Death Dis"},{"key":"2310_CR144","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-animal-021419-083831","volume":"9","author":"S Muyldermans","year":"2021","unstructured":"Muyldermans S. Applications of nanobodies. Annu Rev Anim Biosci. 2021;9:401\u201321. https:\/\/doi.org\/10.1146\/annurev-animal-021419-083831.","journal-title":"Annu Rev Anim Biosci"},{"issue":"4","key":"2310_CR145","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaci.2024.05.027","volume":"154","author":"M Zhu","year":"2024","unstructured":"Zhu M, Ma L, Zhong P, et al. A novel inhalable nanobody targeting IL-4R\u03b1 for the treatment of asthma. J Allergy Clin Immunol. 2024;154(4):1008\u201321. https:\/\/doi.org\/10.1016\/j.jaci.2024.05.027.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2310_CR146","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1165\/rcmb.2012-0500OC","volume":"49","author":"MT Kasaian","year":"2013","unstructured":"Kasaian MT, Marquette K, Fish S, et al. An IL-4\/IL-13 dual antagonist reduces lung inflammation, airway hyperresponsiveness, and IgE production in mice. Am J Respir Cell Mol Biol. 2013;49(1):37\u201346. https:\/\/doi.org\/10.1165\/rcmb.2012-0500OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"2310_CR147","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01461-2024","volume":"65","author":"A Deiteren","year":"2025","unstructured":"Deiteren A, Krupka E, Bontinck L, et al. A proof-of-mechanism trial in asthma with Lunsekimig, a bispecific NANOBODY molecule. Eur Respir J. 2025;65(4):2401461. https:\/\/doi.org\/10.1183\/13993003.01461-2024.","journal-title":"Eur Respir J"},{"issue":"2","key":"2310_CR148","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jaip.2025.08.022","volume":"14","author":"A Tomasello","year":"2026","unstructured":"Tomasello A, Szefler SJ, Cahill KN. Emerging systemic treatments for asthma and allergic diseases: new tricks, same dog? J Allergy Clin Immunol Pract. 2026;14(2):325\u201335. https:\/\/doi.org\/10.1016\/j.jaip.2025.08.022.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"22","key":"2310_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/cells14221747","volume":"14","author":"M Yu","year":"2025","unstructured":"Yu M, Chen P, Jin Y, et al. A bispecific antibody blocking both TSLP and IL-4R\u03b1 for the treatment of allergic inflammatory diseases. Cells. 2025;14(22):1747. https:\/\/doi.org\/10.3390\/cells14221747.","journal-title":"Cells"},{"issue":"5","key":"2310_CR150","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/13543784.2023.2215425","volume":"32","author":"MG Matera","year":"2023","unstructured":"Matera MG, Ora J, Calzetta L, Rogliani P, Cazzola M. Investigational anti IL-13 asthma treatments: a 2023 update. Expert Opin Investig Drugs. 2023;32(5):373\u201386. https:\/\/doi.org\/10.1080\/13543784.2023.2215425.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"2310_CR151","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s12325-017-0525-8","volume":"34","author":"CS Tripp","year":"2017","unstructured":"Tripp CS, Cuff C, Campbell AL, et al. RPC4046, a novel anti-interleukin-13 antibody, blocks IL-13 binding to IL-13 \u03b11 and \u03b12 receptors: a randomized, double-blind, placebo-controlled, dose-escalation first-in-human study. Adv Ther. 2017;34(6):1364\u201381. https:\/\/doi.org\/10.1007\/s12325-017-0525-8.","journal-title":"Adv Ther"},{"issue":"5","key":"2310_CR152","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1365-2125.2012.04477.x","volume":"75","author":"B van Hartingsveldt","year":"2013","unstructured":"van Hartingsveldt B, Nnane IP, Bouman-Thio E, et al. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013;75(5):1289\u201398. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04477.x.","journal-title":"Br J Clin Pharmacol"},{"key":"2310_CR153","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ebiom.2018.07.035","volume":"35","author":"G Burgess","year":"2018","unstructured":"Burgess G, Boyce M, Jones M, et al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018;35:67\u201375. https:\/\/doi.org\/10.1016\/j.ebiom.2018.07.035.","journal-title":"EBioMedicine"},{"key":"2310_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109677","volume":"253","author":"F Cevikbas","year":"2023","unstructured":"Cevikbas F, Ward A, Firth C, Veverka K. Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clin Immunol. 2023;253:109677. https:\/\/doi.org\/10.1016\/j.clim.2023.109677.","journal-title":"Clin Immunol"},{"issue":"6","key":"2310_CR155","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40259-024-00685-y","volume":"38","author":"F Cevikbas","year":"2024","unstructured":"Cevikbas F, Ward A, Veverka KA. Eblasakimab, an anti-IL-13R\u03b11 antibody, reduces atopy-associated serum biomarkers in moderate-to-severe atopic dermatitis. BioDrugs. 2024;38(6):821\u201330. https:\/\/doi.org\/10.1007\/s40259-024-00685-y.","journal-title":"BioDrugs"},{"issue":"3","key":"2310_CR156","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01193-2022","volume":"61","author":"GM Gauvreau","year":"2023","unstructured":"Gauvreau GM, Hohlfeld JM, FitzGerald JM, et al. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. Eur Respir J. 2023;61(3):2201193. https:\/\/doi.org\/10.1183\/13993003.01193-2022.","journal-title":"Eur Respir J"},{"key":"2310_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2022.102184","volume":"78","author":"PM O\u2019Byrne","year":"2023","unstructured":"O\u2019Byrne PM, Panettieri RA Jr, Taube C, Brindicci C, Fleming M, Altman P. Development of an inhaled anti-TSLP therapy for asthma. Pulm Pharmacol Ther. 2023;78:102184. https:\/\/doi.org\/10.1016\/j.pupt.2022.102184.","journal-title":"Pulm Pharmacol Ther"},{"key":"2310_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2025.1700060","volume":"6","author":"HK Komori","year":"2025","unstructured":"Komori HK, Ortega H. Potential of alarmin-targeted bispecific and combination therapies in airway disease. Front Allergy. 2025;6:1700060. https:\/\/doi.org\/10.3389\/falgy.2025.1700060.","journal-title":"Front Allergy"},{"issue":"5","key":"2310_CR159","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jaci.2025.06.024","volume":"156","author":"M Zhu","year":"2025","unstructured":"Zhu M, Ma L, Gai J, et al. Preclinical and phase I randomized study of a potent inhalable nanobody targeting TSLP for the treatment of airway inflammation. J Allergy Clin Immunol. 2025;156(5):1314-27.e7. https:\/\/doi.org\/10.1016\/j.jaci.2025.06.024.","journal-title":"J Allergy Clin Immunol"},{"key":"2310_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115474","volume":"165","author":"HL Shen","year":"2025","unstructured":"Shen HL, Wang XL, Liu YH, et al. Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7R\u03b1 with a biparatopic nanobody. Int Immunopharmacol. 2025;165:115474. https:\/\/doi.org\/10.1016\/j.intimp.2025.115474.","journal-title":"Int Immunopharmacol"},{"key":"2310_CR161","doi-asserted-by":"publisher","first-page":"A1393","DOI":"10.1164\/ajrccm.2025.211","volume":"211","author":"H Komori","year":"2025","unstructured":"Komori H, Lore M, Postlethwaite H, Manga V, Wittmer L, Ortega H. A differentiated anti-TSLP antibody, provides distinct epitope binding profile and superior potency compared to tezepelumab [abstract]. Am J Respir Crit Care Med. 2025;211:A1393. https:\/\/doi.org\/10.1164\/ajrccm.2025.211.","journal-title":"Am J Respir Crit Care Med"},{"key":"2310_CR162","doi-asserted-by":"publisher","first-page":"A1386","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1386","volume":"209","author":"S Doffman","year":"2024","unstructured":"Doffman S, Dosanjh D, Sadiq M, et al. Phase 1 safety and efficacy of AZD8630\/AMG 104 inhaled anti-TSLP in healthy volunteers and patients with asthma on medium-high dose inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) with elevated baseline fractional exhaled nitric oxide (FeNO) [abstract]. Am J Respir Crit Care Med. 2024;209:A1386. https:\/\/doi.org\/10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1386.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. 68","key":"2310_CR163","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2024.PA3558","volume":"64","author":"S Asimus","year":"2024","unstructured":"Asimus S, Sadiq WM, Cooper J, et al. Pharmacokinetics of AZD8630\/AMG 104 inhaled anti-TSLP in healthy adults and asthma patients. Eur Respir J. 2024;64(Suppl. 68):PA3558. https:\/\/doi.org\/10.1183\/13993003.congress-2024.PA3558.","journal-title":"Eur Respir J"},{"issue":"1","key":"2310_CR164","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1124\/jpet.121.000686","volume":"380","author":"M Numazaki","year":"2022","unstructured":"Numazaki M, Abe M, Hanaoka K, Imamura E, Maeda M, Kimura A, et al. ASP7266, a novel antibody against human thymic stromal lymphopoietin receptor for the treatment of allergic diseases. J Pharmacol Exp Ther. 2022;380(1):26\u201333. https:\/\/doi.org\/10.1124\/jpet.121.000686.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2310_CR165","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cpt.70156","volume":"119","author":"D Singh","year":"2026","unstructured":"Singh D, Brickman CM, Lloyd P, et al. Verekitug, a novel antibody antagonist to the TSLP receptor in adults with asthma: a 32-week randomized phase 1b multiple ascending-dose trial. Clin Pharmacol Ther. 2026;119(3):782\u201390. https:\/\/doi.org\/10.1002\/cpt.70156.","journal-title":"Clin Pharmacol Ther"},{"key":"2310_CR166","doi-asserted-by":"publisher","first-page":"1442588","DOI":"10.3389\/fimmu.2024.1442588149","volume":"15","author":"L Shi","year":"2024","unstructured":"Shi L, Yu M, Jin Y, et al. A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases. Front Immunol. 2024;15:1442588. https:\/\/doi.org\/10.3389\/fimmu.2024.1442588149.","journal-title":"Front Immunol"},{"issue":"1","key":"2310_CR167","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/jcph.6115","volume":"65","author":"C Han","year":"2025","unstructured":"Han C, Fung I, Zhang D, et al. Phase 1 safety and pharmacokinetics study of TAVO101, an anti-human thymic stromal lymphopoietin antibody for the treatment of allergic inflammatory conditions. J Clin Pharmacol. 2025;65(1):28\u201340. https:\/\/doi.org\/10.1002\/jcph.6115.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2310_CR168","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40259-025-00714-4","volume":"39","author":"Y Di","year":"2025","unstructured":"Di Y, Yang L, Zhou J, et al. Translational investigation of CM326 from preclinical studies to randomized phase I clinical trials in healthy adults. BioDrugs. 2025;39(3):487\u201398. https:\/\/doi.org\/10.1007\/s40259-025-00714-4.","journal-title":"BioDrugs"},{"issue":"1","key":"2310_CR169","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.1038\/s41467-025-63682-x","volume":"16","author":"M Xian","year":"2025","unstructured":"Xian M, Lan F, Yan B, et al. An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial. Nat Commun. 2025;16(1):8607. https:\/\/doi.org\/10.1038\/s41467-025-63682-x.","journal-title":"Nat Commun"},{"issue":"1","key":"2310_CR170","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/13543784.2024.2305144","volume":"33","author":"P Rogliani","year":"2024","unstructured":"Rogliani P, Manzetti GM, Bettin FR, D\u2019Auria M, Calzetta L. Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review. Expert Opin Investig Drugs. 2024;33(1):39\u201349. https:\/\/doi.org\/10.1080\/13543784.2024.2305144.","journal-title":"Expert Opin Investig Drugs"},{"key":"2310_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00364","volume":"10","author":"BCL Chan","year":"2019","unstructured":"Chan BCL, Lam CWK, Tam LS, Wong CK. IL33: roles in allergic inflammation and therapeutic perspectives. Front Immunol. 2019;10:364. https:\/\/doi.org\/10.3389\/fimmu.2019.00364.","journal-title":"Front Immunol"},{"key":"2310_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155891","volume":"156","author":"C Cayrol","year":"2022","unstructured":"Cayrol C, Girard JP. Interleukin-33 (IL-33): a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. Cytokine. 2022;156:155891. https:\/\/doi.org\/10.1016\/j.cyto.2022.155891.","journal-title":"Cytokine"},{"key":"2310_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1436437","volume":"15","author":"S Gu","year":"2024","unstructured":"Gu S, Wang R, Zhang W, et al. The production, function, and clinical applications of IL-33 in type 2 inflammation-related respiratory diseases. Front Immunol. 2024;15:1436437. https:\/\/doi.org\/10.3389\/fimmu.2024.1436437.","journal-title":"Front Immunol"},{"issue":"18","key":"2310_CR174","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","volume":"385","author":"ME Wechsler","year":"2021","unstructured":"Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021;385(18):1656\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2024257.","journal-title":"N Engl J Med"},{"issue":"Suppl.\u202f106","key":"2310_CR175","doi-asserted-by":"publisher","DOI":"10.1111\/all.13958","volume":"74","author":"M Londei","year":"2019","unstructured":"Londei M, Marquette-Hamoudi A, Phenis K, Pinkstaff J, Sacco N, Pavord I. Single-dose phase 2a trial of etokimab (anti-IL-33) in severe eosinophilic asthma [abstract LBOA1714]. Allergy. 2019;74(Suppl.\u202f106):128. https:\/\/doi.org\/10.1111\/all.13958.","journal-title":"Allergy"},{"issue":"2","key":"2310_CR176","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1358\/dof.2023.48.2.3474010","volume":"48","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Rogliani P, Calzetta L, Matera MG. Tozorakimab. Anti-IL-33 monoclonal antibody, treatment of COPD and asthma, treatment of atopic dermatitis, treatment of diabetic kidney disease. Drugs Future. 2023;48(2):101\u20139. https:\/\/doi.org\/10.1358\/dof.2023.48.2.3474010.","journal-title":"Drugs Future"},{"issue":"Suppl. 2","key":"2310_CR177","doi-asserted-by":"publisher","first-page":"A65","DOI":"10.1136\/thorax-2024-BTSabstracts.96","volume":"79","author":"J Corren","year":"2024","unstructured":"Corren J, Reid F, Moate R, et al. S90 FRONTIER-3: a randomized, phase 2a study to evaluate the efficacy and safety of tozorakimab (an anti-interleukin-33 monoclonal antibody) in early-onset asthma. Thorax. 2024;79(Suppl. 2):A65\u20136. https:\/\/doi.org\/10.1136\/thorax-2024-BTSabstracts.96.","journal-title":"Thorax"},{"issue":"3","key":"2310_CR178","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","volume":"148","author":"SG Kelsen","year":"2021","unstructured":"Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol. 2021;148(3):790\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2021.03.044.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2310_CR179","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jacig.2022.07.002","volume":"1","author":"C Crim","year":"2022","unstructured":"Crim C, Stone S, Millar V, et al. IL-33 receptor inhibition in subjects with uncontrolled asthma: a randomized, placebo-controlled trial. J Allergy Clin Immunol Glob. 2022;1(4):198\u2013208. https:\/\/doi.org\/10.1016\/j.jacig.2022.07.002.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"2","key":"2310_CR180","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281205","volume":"18","author":"C Akinseye","year":"2023","unstructured":"Akinseye C, Crim C, Newlands A, Fairman D. Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: a phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial. PLoS ONE. 2023;18(2):e0281205. https:\/\/doi.org\/10.1371\/journal.pone.0281205.","journal-title":"PLoS ONE"},{"issue":"7","key":"2310_CR181","doi-asserted-by":"publisher","DOI":"10.3390\/biom15070996","volume":"15","author":"P Plewa","year":"2025","unstructured":"Plewa P, Pokwicka J, Bakinowska E, Kie\u0142bowski K, Pawlik A. The role of alarmins in the pathogenesis of asthma. Biomolecules. 2025;15(7):996. https:\/\/doi.org\/10.3390\/biom15070996.","journal-title":"Biomolecules"},{"issue":"1","key":"2310_CR182","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaci.2020.12.628","volume":"148","author":"J Borowczyk","year":"2021","unstructured":"Borowczyk J, Shutova M, Brembilla NC, Boehncke WH. IL-25 (IL-17E) in epithelial immunology and pathophysiology. J Allergy Clin Immunol. 2021;148(1):40\u201352. https:\/\/doi.org\/10.1016\/j.jaci.2020.12.628.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2310_CR183","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00474-9","volume":"11","author":"Q Yuan","year":"2023","unstructured":"Yuan Q, Peng N, Xiao F, et al. New insights into the function of interleukin-25 in disease pathogenesis. Biomark Res. 2023;11(1):36. https:\/\/doi.org\/10.1186\/s40364-023-00474-9.","journal-title":"Biomark Res"},{"issue":"6","key":"2310_CR184","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jaci.2007.07.051","volume":"120","author":"SJ Ballantyne","year":"2007","unstructured":"Ballantyne SJ, Barlow JL, Jolin HE, et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 2007;120(6):1324\u201331. https:\/\/doi.org\/10.1016\/j.jaci.2007.07.051.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2310_CR185","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02509-z","volume":"24","author":"X Yao","year":"2023","unstructured":"Yao X, Chen Q, Wang X, Liu X, Zhang L. IL-25 induces airway remodeling in asthma by orchestrating the phenotypic changes of epithelial cell and fibrocyte. Respir Res. 2023;24(1):212. https:\/\/doi.org\/10.1186\/s12931-023-02509-z.","journal-title":"Respir Res"},{"issue":"1-2","key":"2310_CR186","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/13543784.2025.2453162","volume":"34","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zheng W, Peng R, et al. First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers. Expert Opin Investig Drugs. 2025;34(1\u20132):81\u20137. https:\/\/doi.org\/10.1080\/13543784.2025.2453162.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"2310_CR187","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/all.16120","volume":"79","author":"LH Lam","year":"2024","unstructured":"Lam LH, Li W, Wu WC, et al. SM17, a new IL-17RB-targeting antibody, ameliorates disease progression in a mouse model of atopic dermatitis. Allergy. 2024;79(6):1625\u20138. https:\/\/doi.org\/10.1111\/all.16120.","journal-title":"Allergy"},{"key":"2310_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1495540","volume":"15","author":"G Xu","year":"2024","unstructured":"Xu G, Paglialunga S, Qian X, et al. Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trial. Front Immunol. 2024;15:1495540. https:\/\/doi.org\/10.3389\/fimmu.2024.1495540.","journal-title":"Front Immunol"},{"key":"2310_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1070779","volume":"14","author":"Z Kanannejad","year":"2023","unstructured":"Kanannejad Z, Soleimanian S, Ghahramani Z, et al. Immune checkpoint molecules in prevention and development of asthma. Front Immunol. 2023;14:1070779. https:\/\/doi.org\/10.3389\/fimmu.2023.1070779.","journal-title":"Front Immunol"},{"issue":"4","key":"2310_CR190","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/all.13602","volume":"74","author":"FI Uwadiae","year":"2019","unstructured":"Uwadiae FI, Pyle CJ, Walker SA, Lloyd CM, Harker JA. Targeting the ICOS\/ICOS-L pathway in a mouse model of established allergic asthma disrupts T follicular helper cell responses and ameliorates disease. Allergy. 2019;74(4):650\u201362. https:\/\/doi.org\/10.1111\/all.13602.","journal-title":"Allergy"},{"issue":"2","key":"2310_CR191","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1378\/chest.11-1730","volume":"141","author":"D Kaur","year":"2012","unstructured":"Kaur D, Brightling C. OX40\/OX40 ligand interactions in T-cell regulation and asthma. Chest. 2012;141(2):494\u20139. https:\/\/doi.org\/10.1378\/chest.11-1730.","journal-title":"Chest"},{"issue":"7","key":"2310_CR192","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1046\/j.1365-2222.1997.700840.x","volume":"27","author":"C Leonard","year":"1997","unstructured":"Leonard C, Tormey V, Faul J, Burke CM, Poulter LW. Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy. 1997;27(7):780\u20136. https:\/\/doi.org\/10.1046\/j.1365-2222.1997.700840.x.","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"2310_CR193","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.4049\/jimmunol.1103581","volume":"189","author":"M Busse","year":"2012","unstructured":"Busse M, Krech M, Meyer-Bahlburg A, Hennig C, Hansen G. ICOS mediates the generation and function of CD4+CD25+Foxp3+ regulatory T cells conveying respiratory tolerance. J Immunol. 2012;189(4):1975\u201382. https:\/\/doi.org\/10.4049\/jimmunol.1103581.","journal-title":"J Immunol"},{"issue":"4","key":"2310_CR194","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.4049\/jimmunol.1000024","volume":"185","author":"X Sun","year":"2010","unstructured":"Sun X, Yamada H, Shibata K, et al. CD30 ligand\/CD30 plays a critical role in Th17 differentiation in mice. J Immunol. 2010;185(4):2222\u201330. https:\/\/doi.org\/10.4049\/jimmunol.1000024.","journal-title":"J Immunol"},{"issue":"10","key":"2310_CR195","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1002\/eji.201141423","volume":"41","author":"T Fuchiwaki","year":"2011","unstructured":"Fuchiwaki T, Sun X, Fujimura K, et al. The central role of CD30L\/CD30 interactions in allergic rhinitis pathogenesis in mice. Eur J Immunol. 2011;41(10):2947\u201354. https:\/\/doi.org\/10.1002\/eji.201141423.","journal-title":"Eur J Immunol"},{"issue":"21","key":"2310_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111898","volume":"22","author":"MA Galv\u00e1n Morales","year":"2021","unstructured":"Galv\u00e1n Morales MA, Montero-Vargas JM, Vizuet-de-Rueda JC, Teran LM. New insights into the role of PD-1 and its ligands in allergic disease. Int J Mol Sci. 2021;22(21):11898. https:\/\/doi.org\/10.3390\/ijms222111898.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2310_CR197","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/eji.201445163","volume":"45","author":"KE Burrows","year":"2015","unstructured":"Burrows KE, Dumont C, Thompson CL, Catley MC, Dixon KL, Marshall D. OX40 blockade inhibits house dust mite driven allergic lung inflammation in mice and in vitro allergic responses in humans. Eur J Immunol. 2015;45(4):1116\u201328. https:\/\/doi.org\/10.1002\/eji.201445163.","journal-title":"Eur J Immunol"},{"issue":"6","key":"2310_CR198","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jaci.2024.12.1097","volume":"155","author":"GS Sethi","year":"2025","unstructured":"Sethi GS, Ramamoorthy Premlal AL, Chawla A, Croft M. ICOSL, OX40L, and CD30L control persistence of asthmatic CD4 tissue-resident memory CD4 T cells. J Allergy Clin Immunol. 2025;155(6):1993\u20132008. https:\/\/doi.org\/10.1016\/j.jaci.2024.12.1097.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2310_CR199","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/cea.12235","volume":"44","author":"GM Gauvreau","year":"2014","unstructured":"Gauvreau GM, Boulet LP, Cockcroft DW, et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy. 2014;44(1):29\u201337. https:\/\/doi.org\/10.1111\/cea.12235.","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"2310_CR200","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics1412753","volume":"14","author":"AM L\u00e9","year":"2022","unstructured":"L\u00e9 AM, Torres T. OX40-OX40L inhibition for the treatment of atopic dermatitis: focus on rocatinlimab and amlitelimab. Pharmaceutics. 2022;14(12):2753. https:\/\/doi.org\/10.3390\/pharmaceutics1412753.","journal-title":"Pharmaceutics"},{"issue":"10523","key":"2310_CR201","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(25)01865-3","volume":"407","author":"E Guttman-Yassky","year":"2026","unstructured":"Guttman-Yassky E, Kabashima K, Worm M, et al. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet. 2026;407(10523):53\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(25)01865-3.","journal-title":"Lancet"},{"issue":"4","key":"2310_CR202","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/eji.201444778","volume":"45","author":"JW McAlees","year":"2015","unstructured":"McAlees JW, Lajoie S, Dienger K, et al. Differential control of CD4(+) T-cell subsets by the PD-1\/PD-L1 axis in a mouse model of allergic asthma. Eur J Immunol. 2015;45(4):1019\u201329. https:\/\/doi.org\/10.1002\/eji.201444778.","journal-title":"Eur J Immunol"},{"issue":"9","key":"2310_CR203","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.4049\/jimmunol.174.9.5774","volume":"174","author":"SJ McMillan","year":"2005","unstructured":"McMillan SJ, Xanthou G, Lloyd CM. Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway. J Immunol. 2005;174(9):5774\u201380. https:\/\/doi.org\/10.4049\/jimmunol.174.9.5774.","journal-title":"J Immunol"},{"issue":"2","key":"2310_CR204","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1165\/rcmb.2010-0027TR","volume":"44","author":"R Halwani","year":"2011","unstructured":"Halwani R, Al-Muhsen S, Al-Jahdali H, Hamid Q. Role of transforming growth factor-\u03b2 in airway remodeling in asthma. Am J Respir Cell Mol Biol. 2011;44(2):127\u201333. https:\/\/doi.org\/10.1165\/rcmb.2010-0027TR.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"2310_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051837","volume":"21","author":"I Janulaityte","year":"2020","unstructured":"Janulaityte I, Januskevicius A, Kalinauskaite-Zukauske V, Bajoriuniene I, Malakauskas K. In vivo allergen-activated eosinophils promote collagen I and fibronectin gene expression in airway smooth muscle cells via TGF-\u03b21 signaling pathway in asthma. Int J Mol Sci. 2020;21(5):1837. https:\/\/doi.org\/10.3390\/ijms21051837.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2310_CR206","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043469","volume":"24","author":"A Rimkunas","year":"2023","unstructured":"Rimkunas A, Januskevicius A, Vasyle E, et al. Blood inflammatory-like and lung resident-like eosinophils affect migration of airway smooth muscle cells and their ECM-related proliferation in asthma. Int J Mol Sci. 2023;24(4):3469. https:\/\/doi.org\/10.3390\/ijms24043469.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2310_CR207","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","volume":"9","author":"S Diver","year":"2021","unstructured":"Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299\u2013312. https:\/\/doi.org\/10.1016\/S2213-2600(21)00226-5.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2310_CR208","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009674","volume":"5","author":"SE Bottoms","year":"2010","unstructured":"Bottoms SE, Howell JE, Reinhardt AK, Evans IC, McAnulty RJ. Tgf-Beta isoform specific regulation of airway inflammation and remodelling in a murine model of asthma. PLoS ONE. 2010;5(3):e9674. https:\/\/doi.org\/10.1371\/journal.pone.0009674.","journal-title":"PLoS ONE"},{"key":"2310_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107666","volume":"217","author":"BA Teicher","year":"2021","unstructured":"Teicher BA. TGF\u03b2-directed therapeutics: 2020. Pharmacol Ther. 2021;217:107666. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107666.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2310_CR210","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/toxsci\/kfaf059","volume":"206","author":"MS Mitra","year":"2025","unstructured":"Mitra MS, Halpern W, Lepherd M, et al. Dual inhibition of TGF\u03b22,3 is severely toxic, whereas selective inhibition of TGF\u03b21,2, or 3 and dual inhibition of TGF\u03b21,2 is generally tolerated in mouse and cynomolgus monkey toxicology studies. Toxicol Sci. 2025;206(2):445\u201355. https:\/\/doi.org\/10.1093\/toxsci\/kfaf059.","journal-title":"Toxicol Sci"},{"issue":"10","key":"2310_CR211","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1164\/rccm.200702-334OC","volume":"176","author":"JF Alcorn","year":"2007","unstructured":"Alcorn JF, Rinaldi LM, Jaffe EF, et al. Transforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease. Am J Respir Crit Care Med. 2007;176(10):974\u201382. https:\/\/doi.org\/10.1164\/rccm.200702-334OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2310_CR212","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1111\/jcmm.13576","volume":"22","author":"J Wang","year":"2018","unstructured":"Wang J, Faiz A, Ge Q, et al. Unique mechanisms of connective tissue growth factor regulation in airway smooth muscle in asthma: relationship with airway remodelling. J Cell Mol Med. 2018;22(5):2826\u201337. https:\/\/doi.org\/10.1111\/jcmm.13576.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2310_CR213","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1183\/13993003.01030-2015","volume":"47","author":"G Raghu","year":"2016","unstructured":"Raghu G, Scholand MB, de Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47(5):1481\u201391. https:\/\/doi.org\/10.1183\/13993003.01030-2015.","journal-title":"Eur Respir J"},{"issue":"12","key":"2310_CR214","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113980","volume":"9","author":"W Gao","year":"2014","unstructured":"Gao W, Cai L, Xu X, et al. Anti-CTGF single-chain variable fragment dimers inhibit human airway smooth muscle (ASM) cell proliferation by down-regulating p-Akt and p-mTOR levels. PLoS ONE. 2014;9(12):e113980. https:\/\/doi.org\/10.1371\/journal.pone.0113980.","journal-title":"PLoS ONE"},{"issue":"1","key":"2310_CR215","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04361-2020","volume":"60","author":"J Ramis","year":"2022","unstructured":"Ramis J, Middlewick R, Pappalardo F, et al. Lysyl oxidase like 2 is increased in asthma and contributes to asthmatic airway remodelling. Eur Respir J. 2022;60(1):2004361. https:\/\/doi.org\/10.1183\/13993003.04361-2020.","journal-title":"Eur Respir J"},{"issue":"1","key":"2310_CR216","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-024-02811-4","volume":"25","author":"R Zeng","year":"2024","unstructured":"Zeng R, Zhang D, Zhang J, et al. Targeting lysyl oxidase like 2 attenuates OVA-induced airway remodeling partly via the AKT signaling pathway. Respir Res. 2024;25(1):230. https:\/\/doi.org\/10.1186\/s12931-024-02811-4.","journal-title":"Respir Res"},{"issue":"2","key":"2310_CR217","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.31236","volume":"72","author":"W Chen","year":"2020","unstructured":"Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H. Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis. Hepatology. 2020;72(2):729\u201341. https:\/\/doi.org\/10.1002\/hep.31236.","journal-title":"Hepatology"},{"key":"2310_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173754","volume":"892","author":"A Matsuo","year":"2021","unstructured":"Matsuo A, Tanida R, Yanagi S, et al. Significance of nuclear LOXL2 inhibition in fibroblasts and myofibroblasts in the fibrotic process of acute respiratory distress syndrome. Eur J Pharmacol. 2021;892:173754. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173754.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2310_CR219","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","volume":"165","author":"S Hansen","year":"2024","unstructured":"Hansen S, Baastrup S\u00f8ndergaard M, von B\u00fclow A, et al. Clinical response and remission in patients with severe asthma treated with biologic therapies. Chest. 2024;165(2):253\u201366. https:\/\/doi.org\/10.1016\/j.chest.2023.10.046.","journal-title":"Chest"},{"issue":"1","key":"2310_CR220","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jaci.2023.07.025","volume":"153","author":"KA Dill-McFarland","year":"2024","unstructured":"Dill-McFarland KA, Altman MC, Esnault S, Jarjour NN, Busse WW, Rosenkranz MA. Molecular pathways underlying lung-brain axis signaling in asthma: relevance for psychopathology and neuroinflammation. J Allergy Clin Immunol. 2024;153(1):111\u201321. https:\/\/doi.org\/10.1016\/j.jaci.2023.07.025.","journal-title":"J Allergy Clin Immunol"},{"key":"2310_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105063","volume":"146","author":"JL Kroll","year":"2023","unstructured":"Kroll JL, Ritz T. Asthma, the central nervous system, and neurocognition: current findings, potential mechanisms, and treatment implications. Neurosci Biobehav Rev. 2023;146:105063. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105063.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"2310_CR222","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.chest.2025.08.042","volume":"169","author":"AJ Oberle","year":"2026","unstructured":"Oberle AJ, Abbas F, Adrish M, et al. Biologic management in severe asthma for adults: an American College of Chest Physicians clinical practice guideline. Chest. 2026;169(2):336\u201348. https:\/\/doi.org\/10.1016\/j.chest.2025.08.042.","journal-title":"Chest"},{"issue":"5","key":"2310_CR223","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00260-2020","volume":"56","author":"CM Porsbjerg","year":"2020","unstructured":"Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, Bel EH. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. https:\/\/doi.org\/10.1183\/13993003.00260-2020.","journal-title":"Eur Respir J"},{"issue":"4","key":"2310_CR224","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/ACI.0000000000001081","volume":"25","author":"R Poto","year":"2025","unstructured":"Poto R, Portacci A, Chan R, Lagnese G, Giovannini M, Varricchi G. Advancing precision medicine for asthma by focusing on type 2 cytokines and alarmins. Curr Opin Allergy Clin Immunol. 2025;25(4):269\u201376. https:\/\/doi.org\/10.1097\/ACI.0000000000001081.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"2310_CR225","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70031","volume":"331","author":"A Eggel","year":"2025","unstructured":"Eggel A, Jardetzky TS. Structural and functional insights into IgE receptor interactions and disruptive inhibition. Immunol Rev. 2025;331(1):e70031. https:\/\/doi.org\/10.1111\/imr.70031.","journal-title":"Immunol Rev"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02310-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02310-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02310-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:40:19Z","timestamp":1778856019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02310-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":225,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2310"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02310-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mario Cazzola, Maria Gabriella Matera, Josuel Ora, Luigino Calzetta, and Paola Rogliani have no conflicts of interest that are directly relevant to the content of this article. Mario Cazzola and Luigino Calzetta are Editorial Board members of\n                      Drugs\n                      . Mario Cazzola and Luigino Calzetta were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors were involved in the initial conception of the manuscript. MC and MGM supervised the project. All authors searched and screened all relevant literature. MC and MGM conducted the data extraction and collection. All authors performed the data analysis and review. MC drafted the manuscript. MGM, JO, LC, and PR critically revised the content in their respective areas of expertise. All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}